TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Using Affective Differences to Predict Response to Behavioral Treatment for Major Depressive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy participants should have no lifetime history of psychiatric disorder~* Depressed participants should have a current diagnosis of major depressive disorder, as defined by the DSM-IV~Exclusion Criteria:~* History of bipolar affective disorder~* History of psychosis~* Current non-psychotic Axis I disorder, if it constitutes the predominant aspect of the clinical presentation and immediately requires treatment other than that offered in the study~* History of substance dependence within the past 6 months~* Antisocial, borderline, schizotypal, or schizoid personality disorders~* Evidence of any medical disorder or condition that could cause depression or preclude the use of study treatments~* Current treatment with catecholaminergic antihypertensive medication, such as reserpine, beta-blockers, clonidine, and alphamethyldopa~* Current use of antidepressant medication~* Clear indication of secondary gain~* Current suicide risk sufficient to preclude treatment on an outpatient basis~* Severe, unstable concurrent psychiatric conditions likely to require hospitalization within 6 months of study entry~* Already receiving a targeted psychotherapy aimed at depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: t

Study Arms:
- Current Major Depressive Disorder (Type: None): Forty-one participants with a primary diagnosis of major depression using the Diagnostic and Statistical Manual of Mental Disorders (4th ed.; DSM-IV) and scores \> 24 on the Inventory of Depressive Symptomatology-Clinician Rated (IDS-C; Rush et al., 1986) were enrolled into a treatment study at Northwestern University's Feinberg School of Medicine in Chicago, Illinois. This group will receive Behavioral Activation psychotherapy.
- Healthy Participants (Type: None): Another 36 participants with no lifetime psychiatric symptoms and scores \< 11 on the IDS-C were tracked prospectively, naturalistically, for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label MNS for Tourette Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed participation in the study called Peripheral induction of inhibitory brain circuits to treat Tourette's: pilot~* Informed consent by adult participant, or assent by child and informed consent by guardian~Exclusion Criteria:~* Has an implanted device that could be affected by electrical current~* Pregnancy known to participant or (for children) to the parent~* Severe or unstable systemic illness~* Factors (such as exaggerated symptom report) that in the judgment of the principal investigator may make the outcome measures inaccurate~* Judged by investigator to be unlikely to complete study procedures

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active MNS (Type: EXPERIMENTAL): Active, self-directed electrical stimulation of the right median nerve

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High-voltage Pulsed Radiofrequency on Gasserian Ganglion to Treat Patients With Primary Trigeminal Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Primary Trigeminal Neuralgia meets the criteria of the International Classification of Headache Disorders.~* 18-75 years old.~* Response to drug treatment poorly or unable to tolerate the side effects of drugs.~* A BNI pain intensity scale score of IV-V.~* Supposed to undergo neurosurgical intervention according to Trigeminal Neuralgia treatment guidelines.~* Agree to participate in this trial and have signed the informed consent.~Exclusion Criteria:~* Abnormal routine blood, liver or kidney functions, abnormal blood biochemistry test, or coagulation disorders.~* Abnormal electrocardiogram or chest X-ray results.~* Severe cardiopulmonary dysfunction.~* Infection at the puncture site.~* History of mental illness, or history of narcotic drug abuse.~* Allergy to local anesthetic drugs or steroids.~* Cannot cooperate with the treatment.~* History of invasive treatments, such as radiofrequency thermocoagulation, chemical ablation, balloon compression surgery, gamma knife treatment, peripheral denervation or microvascular decompression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PRF Group (Type: EXPERIMENTAL): This group will undergo 42°C high-voltage pulsed radiofrequency treatment.
- Nerve Block Group (Type: ACTIVE_COMPARATOR): This group will undergo nerve block treatment with steroid and local anesthesia.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who have received 4 doses of experimental vaccine or control vaccine in phase Ⅲ clinical trials~Exclusion Criteria:~* History of vaccination of other vaccine with poliovirus antigenic components except that of phaseⅢ clinical trial.

- Gender: ALL
- Minimum Age: 48 Months
- Maximum Age: 84 Months
- Healthy Volunteers: None

Study Arms:
- Experimental Group (Type: None): Subjects who have received 4 doses of the experimental vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.
- Control Group (Type: None): Subjects who have received 4 doses of control vaccine (including subjects at the age of 4 years (48 to 54 months) and 5 years (78 to 84 months) after the last vaccination ) will be collected venous blood about 3.0ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Valganciclovir to Reduce T Cell Activation in HIV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with HIV \>1 year in duration.~* Age \>18~* Cytomegalovirus (CMV) antibody positive.~* All Cluster of Differentiation 4 (CD4)+ T cell counts in the last year and at screening \<350 cells/mm3~* On a stable highly addictive antiretroviral therapy (HAART) regimen (DHHS definition) for the preceding 6 months.~  * 90% adherence to antiretroviral therapy within the preceding 30 days.~* Females of childbearing potential must have a negative serum pregnancy test at screening and all subjects must agree to use a double-barrier method of contraception throughout the study period.~* Screening %Cluster of differentiation 38 (CD38)+ Human leukocyte antigen-D-related (HLA-DR)+ Cluster of differentiation 8 (CD8)+ T cells \>10%~Exclusion Criteria:~* Patients intending to modify antiretroviral therapy in the next 16 weeks.~* Serious illness requiring hospitalization or parental antibiotics within preceding 3 months.~* Evidence of active symptomatic CMV end-organ disease.~* Treatment with valganciclovir or ganciclovir in the past 30 days.~* Concurrent treatment with immunomodulatory drugs.~* Concurrent treatment with nephrotoxic drugs~* Screening absolute neutrophil count \<1,000 cells/mm3, platelet count \<100,000 cells/mm3, hemoglobin \< 8mg/dL, estimated creatinine clearance \<50 mL/minute.~* Men who are considering having children will also be excluded given potential effects of valganciclovir on spermatogenesis.~* Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Valganciclovir (Type: EXPERIMENTAL): 900mg PO qd
- Placebo (Type: PLACEBO_COMPARATOR): 900mg PO qd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Erythropoietin (EPO) in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hohen and Yahr´s Scale between I and III~* One or more years of evolution of PD,~* Good response to levodopa (more that 30 % of change)valued in motor UPDRS~* An acceptable general health status,~Exclusion Criteria:~* Chronic psychiatric or other neurological diseases.~* Previous polyglobulin~* Hematocryte, same or inferior to 50

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Erythropoietin (Type: EXPERIMENTAL): There are evidences of neuroprotecting therapeutic alternatives in such substances as erythropoietin (EPO) which is a well-known cytokine as a hematopoietic growth factor, so, it is therefore important to control tissular oxygenation. It is considered that EPO protects the neurons by a combination of several mechanisms.~EPOrh is used with high effectiveness in the treatment of anemias with deficiency of erythropoietin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected~* Current severe CDC Category B AIDS-defining illness (with the exception of a single episode of bacterial sepsis or a single episode of zoster), OR history of a severe CDC Category B or C AIDS-defining illness, OR one CD4 count less than 350 cells/mm3 within 6 months prior to study entry~* Antiretroviral naive. A participant who previously received 6 weeks or less of post-exposure prophylaxis or short course therapy for the prevention of mother-to-child transmission are not excluded. More information on this criterion can be found in the protocol.~* Willing to use acceptable forms of contraception~* Parent or guardian willing to provide informed consent, if applicable~Exclusion Criteria:~* Current newly diagnosed CDC Category C AIDS-defining opportunistic infection or condition requiring acute therapy at the time of study entry. More information on this criterion can be found in the protocol.~* Therapy with agents with significant systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or cytotoxic potential within 30 days prior to study entry~* Require certain medications~* Current alcohol or substance abuse that, in the opinion of the investigator, may interfere with the study~* Uncontrolled diarrhea (more than 6 stools per day for 7 consecutive days) within 30 days prior to study entry~* Diagnosis of or suspected acute hepatitis within 30 days prior to study entry~* Signs or symptoms of bilateral peripheral neuropathy of Grade 2 or greater at screening~* Inability to tolerate oral medication~* Any other clinical condition that, in the opinion of the investigator, may interfere with the study~* In the first trimester of pregnancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Study-specified Antiretroviral regimen under care of HIV-trained medical doctor
- B (Type: ACTIVE_COMPARATOR): Study-specified Antiretroviral regimen under care of HIV-trained primary care nurse

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Assess Safety and Efficacy of Bolus Versus Continuous Infusion of Terlipressin in Acute Variceal Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient with only acute esophageal variceal bleeding (as defined by Asian pacific Association for the study of Liver Disease)~* Informed consent to participate in the study~* Age 18 to 70 years~Exclusion Criteria:~* Pregnant and lactation~* Prior treatment with any vasoactive drugs~* Significant heart or respiratory failure~* Peripheral arteriopathy clinically significant~* Previous heart stroke or significant alteration of the Electrocardiogram~* Hemodynamically unstable~* Refusal to participate in the study~* Hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bolus Terlipressin (Type: EXPERIMENTAL): Injection terlipressin after 2 mg bolus it will be given 2 mg QID
- Terlipressin continuous(4mg/24hours) (Type: ACTIVE_COMPARATOR): Injection terlipressin after 2 mg bolus it will be given 4 mg over 24 hours,and dose will be titrated as per HVPG (Hepatic Venous Pressure Gradient)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nigella Sativa in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with mild COVID19 upper respiratory tract infection and with no evidence of pneumonia~* Adult (18 Years and above)~* Written informed consent prior to initiation of any study procedures by the patient (or legally authorized representative).~* Understands and agrees to comply with planned study procedures.~* Has laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by polymerase chain reaction (PCR) available at KAUH.~Exclusion Criteria:~* Patients with pneumonia or severe illness requiring admission to ICU.~* Severe chronic kidney disease (i.e. estimated glomerular filtration rate (eGFR) \< 30) or end stage renal disease requiring dialysis~* Sever chronic liver disease (Alanine transaminase/aspartate transaminase (ALT/AST) \> 5 times the upper limit of normal).~* Pregnancy or breast feeding.~* Anticipated transfer to another hospital which is not a study site within 72 hours.~* Allergy to any study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NSO (Type: EXPERIMENTAL): Nigella sativa oil 500mg softgel capsules in oral twice daily dose for 10 days
- Control (Type: NO_INTERVENTION): Standard of care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes Following Treatment With SYSTANE® BALANCE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to attend all study visits;~* Must sign an informed consent form;~* Best-corrected visual acuity (BCVA) of 55 letters or better in each eye as assessed using an early treatment diabetic retinopathy study (ETDRS) chart;~* Willing to take study products as directed for entire study;~* Other protocol-specified inclusion criteria may apply.~Exclusion Criteria:~* Women of childbearing potential who are pregnant, plan to become pregnant during the study, breast feeding, or not using adequate birth control methods;~* Contact lens use within 30 days prior to Screening Visit, or unwilling to avoid contact lens use during the course of the study;~* Use of medication excluded by the protocol;~* Diseases, illnesses, infections, or ocular abnormalities excluded by the protocol;~* Ocular surgeries or procedures excluded by the protocol;~* Other protocol-specified exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYSTANE BALANCE (Type: EXPERIMENTAL): Propylene glycol, 0.6% eye drops, 1 drop in each eye 4 times per day for 35 days
- REFRESH OPTIVE (Type: ACTIVE_COMPARATOR): Lubricant eye drops, 1 drop in each eye 4 times per day for 35 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Virtual Psychiatric Transition of Care Offered in Behavioral Health

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residency or shelter in North Carolina~* 18 years of age or older on the day of discharge~* Access virtual care (phone/video)~* Discharged from a behavioral health hospital or a behavioral health unit~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Virtual program (Type: EXPERIMENTAL): Seen at a location where the virtual program is being offered
- Standard care (Type: NO_INTERVENTION): Seen at a location where standard care is offered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed small cell lung cancer,extensive stage disease.~* Measurable or evaluable disease~* No previous chemotherapy~* Able to perform activities of daily living with minimal assistance~* Adequate hematological, live and kidney function~* Provide written informed consent~Exclusion Criteria:~* Limited stage disease~* PEG or G tubes~* Hemoptysis~* Abdominal fistula, perforation, or abscess within the previous 6 months~* Women who are pregnant or lactating~* Proteinuria~* Serious nonhealing wound, ulcer, or bone fracture~* Evidence of bleeding diathesis or coagulopathy~* Uncontrolled or serious cardiovascular disease~* Uncontrolled brain metastasis~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days; Fine needle aspiration within 7 days~* Patients requiring full-dose anticoagulation must be on a stable dosing schedule prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed Day 28 of either the DRM04-HH04 or DRM04-HH05 study with at least 80% treatment compliance~* Male or females~Exclusion Criteria:~* Subject has a clinically significant abnormality on physical exam, vital signs or ECG at the Week 4 visit of DRM04-HH04 or DRM04-HH05 study that would make further treatment with glycopyrronium contraindicated~* Male with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy~* Any other condition which, in the judgement of the Investigator, would put the subject at unacceptable risk for participation in the study

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glycopyrronium (Type: EXPERIMENTAL): Glycopyrronium Topical Wipes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia assessed by SCID-I (DSM-IV) as well as RDC-criteria~* Patient record mention of schizophrenia (ICD-10) at least 5 years previously~* Disability pension due to psychiatric disorder~* At least 3 points on the CGI scale~Exclusion Criteria:~* Epilepsy or a history of unclear seizures~* Stroke~* Parkinson's disease~* AIDS~* Substance addiction or abuse within 3 months prior to enrolment.~* Individuals who are deemed at risk for aggressive behavior or suicide by their clinician~* Pregnant and breast-feeding subjects~* Serious unstable physical illness~* Persons who have been deemed legally incapacitated according to Finnish law (Laki holhoustoimesta 1.4.1999/442, 3. luku, 18 §)~* Individuals who use H2-antagonists as prescribed by a physician~* Known allergy to famotidine or any other component of the Pepcidin® 40 mg tablet~* Glomerular Filtration Rate (GFR) according to the Cockcroft-Gault formula \< 30 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- famotidine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete